Similarly, the treatment of USP7 inhibitors (P5091 or P22077) also suppressed the activation of NF-κB, and a combination of USP7 inhibitors and BTZ triggered the synergistic anti-tumor activity in BTZ-resistant MM cells (Yao et al., 2018). Here, USP7 is linked to neoplasm.